Industry

Approval based on TOPAZ-1 Phase III trial results, which showed IMFINZI combination reduced risk of death by 20% vs. chemotherapy alone WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). The … [Read more…]

Long-term data continue to reinforce benefits of Opdivo (nivolumab)-based combinations Response outcomes data continue to build upon the clinical evidence of Opdualag (nivolumab and relatlimab-rmbw) in advanced melanoma Exploratory analyses in non-small cell lung cancer and urothelial carcinoma support the potential benefit of immunotherapy in earlier stages of cancer PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #ESMO—Bristol Myers Squibb … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Biosimilars Global Market Opportunities And Strategies To 2031” report has been added to ResearchAndMarkets.com’s offering. The global biosimilars market reached a value of nearly $11,418.9 million in 2021, having grown at a compound annual growth rate (CAGR) of 34.8% since 2016. The market is expected to grow from $11,418.9 million in 2021 to … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Recombinant Cell Culture Supplements Market: Focus on Pricing Analysis, Product, Application, Expression System, and Region – Analysis and Forecast, 2022-2032” report has been added to ResearchAndMarkets.com’s offering. The global recombinant cell culture supplements market was estimated at $308.6 million in 2021 and is expected to reach $1,188.6 million by 2032, growing at … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Single-use Bioprocessing Market By Product, By Application, By Method, By End User: Global Opportunity Analysis and Industry Forecast, 2020-2030” report has been added to ResearchAndMarkets.com’s offering. ‘Single-use Bioprocessing Market,’ was valued at $7.0 billion in 2020, and is estimated to reach $38.8 billion by 2030, growing at a CAGR of 18.4% from 2021 … [Read more…]

LONDON & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft … [Read more…]

Onera Health announces the launch of Onera Polysomnography-as-a-Service in selected European markets at the International Congress 2022 of the European Respiratory Society (ERS). EINDHOVEN, The Netherlands–(BUSINESS WIRE)–Onera Health, a leader in transforming sleep medicine and remote monitoring, announced today the official launch of its ground-breaking solution to diagnose sleep disorders in Europe. The service is … [Read more…]

Poster presentation on ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma Oral presentation on multispecific antibodies: ANKET for antigen-specific activation of NK cells by Innate’s Chief Scientific Officer, Eric Vivier, DVM, PhD, AstraZeneca-sponsored Phase 2 NeoCOAST study of neoadjuvant durvalumab alone or combined with novel agents, including monalizumab, in patients with … [Read more…]

EMERYVILLE, Calif.–(BUSINESS WIRE)–SLINGSHOT BIOSCIENCES, INC., the makers of synthetic control cells for cell analysis applications, including flow cytometry, enabling precise, reliable, and repeatable results, today announced they had extended their distribution channel through a new agreement with BIOKÉ, an experienced and knowledgeable company from the Netherlands that provides innovative products with the highest quality in … [Read more…]

Oral presentation in “Investigational Immunotherapy” session on Saturday, September 10 at 2:45 PM CEST MUNICH–(BUSINESS WIRE)–CatalYm today announced that the mature results from its Phase 1, first-in-human trial “GDFATHER-1” (GDF-15 antibody-mediated human effector cell relocation) will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022. The trial evaluated … [Read more…]